- Home
- PCRX vs KROS Comparison
PCRX vs KROS Comparison
Compare PCRX & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- KROS
- Stock Information
- Founded
- PCRX 2006
- KROS 2015
- Country
- PCRX United States
- KROS United States
- Employees
- PCRX N/A
- KROS N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- PCRX Health Care
- KROS Health Care
- Exchange
- PCRX Nasdaq
- KROS Nasdaq
- Market Cap
- PCRX 1.2B
- KROS 558.9M
- IPO Year
- PCRX 2011
- KROS 2020
- Fundamental
- Price
- PCRX $23.22
- KROS $13.45
- Analyst Decision
- PCRX Buy
- KROS Buy
- Analyst Count
- PCRX 8
- KROS 13
- Target Price
- PCRX $28.38
- KROS $20.63
- AVG Volume (30 Days)
- PCRX 569.8K
- KROS 603.2K
- Earning Date
- PCRX 07-29-2025
- KROS 08-06-2025
- Dividend Yield
- PCRX N/A
- KROS N/A
- EPS Growth
- PCRX N/A
- KROS N/A
- EPS
- PCRX N/A
- KROS 0.11
- Revenue
- PCRX $702,772,000.00
- KROS $214,713,000.00
- Revenue This Year
- PCRX $7.54
- KROS $5,006.76
- Revenue Next Year
- PCRX $10.78
- KROS N/A
- P/E Ratio
- PCRX N/A
- KROS $123.44
- Revenue Growth
- PCRX 3.08
- KROS 91657.70
- 52 Week Low
- PCRX $11.16
- KROS $9.12
- 52 Week High
- PCRX $27.64
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- PCRX 35.42
- KROS 43.42
- Support Level
- PCRX $22.82
- KROS $13.24
- Resistance Level
- PCRX $24.36
- KROS $13.77
- Average True Range (ATR)
- PCRX 0.69
- KROS 0.38
- MACD
- PCRX -0.12
- KROS -0.04
- Stochastic Oscillator
- PCRX 17.09
- KROS 28.00
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.